Dare Bioscience Inc Cash Flow Conversion Efficiency
Dare Bioscience Inc cash flow conversion efficiency. Based on the latest financial reports, Dare Bioscience Inc (DARE) has a cash flow conversion efficiency ratio of 0.508x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.44 Million) by net assets ($2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dare Bioscience Inc (2011–2025)
Cash flow conversion efficiency of Dare Bioscience Inc from 2011 to 2025. This chart illustrates how Dare Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Dare Bioscience Inc stock price today for real-time trading data and today's change.
Dare Bioscience Inc Cash Flow Conversion Ratio Explained
Dare Bioscience Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dare Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dare Bioscience Inc ranked by their cash flow conversion efficiency. Also see DARE stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kim Hin Joo
KLSE:0210
|
0.223x |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
0.490x |
|
Intanwijaya Internasional Tbk
JK:INCI
|
0.079x |
|
Euro Kapital Yatirim Ortakligi AS
IS:EUKYO
|
0.141x |
|
Mont Royal Resources Ltd
AU:MRZ
|
-0.018x |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
-0.076x |
|
Lease IT Public Company Limited
BK:LIT
|
-0.330x |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
N/A |
Annual Cash Flow Conversion Efficiency for Dare Bioscience Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Dare Bioscience Inc from 2011 to 2025. Review cash generation quality of Dare Bioscience Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.84 Million | $-9.89 Billion | -3477.715x | -387504.24% |
| 2024-12-31 | $-6.01 Million | $5.39 Million | -0.897x | -111.66% |
| 2023-12-31 | $-5.05 Million | $-38.86 Million | 7.698x | +572.90% |
| 2022-12-31 | $11.11 Million | $-18.09 Million | -1.628x | -119.32% |
| 2021-12-31 | $38.75 Million | $-28.76 Million | -0.742x | -103.39% |
| 2020-12-31 | $-1.15 Million | $-25.23 Million | 21.910x | +172.54% |
| 2019-12-31 | $440.83K | $-13.32 Million | -30.206x | -1878.71% |
| 2018-12-31 | $6.73 Million | $-10.27 Million | -1.527x | -698.85% |
| 2017-12-31 | $13.29 Million | $-2.54 Million | -0.191x | +92.53% |
| 2016-12-31 | $13.11 Million | $-33.54 Million | -2.558x | -290.65% |
| 2015-12-31 | $48.74 Million | $-31.91 Million | -0.655x | -55.70% |
| 2014-12-31 | $45.33 Million | $-19.06 Million | -0.421x | -107.06% |
| 2013-12-31 | $-2.79 Million | $-16.61 Million | 5.959x | +2170.70% |
| 2012-12-31 | $-80.04 Million | $-21.00 Million | 0.262x | +119.21% |
| 2011-12-31 | $12.35 Million | $-16.88 Million | -1.366x | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more